America Invented CAR-T Therapy. Now It's Losing the Race.

Third, political will. China's government has made biotech a strategic priority, pouring money into infrastructure and manufacturing. The result is an ecosystem that moves fast by design, not by accident.

Meanwhile, Back in Washington

While China is stepping on the gas, the U.S. is tapping the brakes on research funding.

The Trump administration proposed cutting the NIH budget by nearly 40% for fiscal year 2026, slashing it from roughly $47 billion down to about $27 billion. That would have been catastrophic. Congress pushed back hard, advancing bipartisan bills that preserved funding around $47 to $48.7 billion, even adding a $415 million increase and keeping $1.5 billion for ARPA-H (the government's moonshot health research agency).

But the damage isn't just in final numbers. The uncertainty itself is corrosive. In FY2025, NIH grant approval rates fell to approximately 20%, roughly half of prior-year levels. Projects focused on cancer, HIV/AIDS, and vaccine research got delayed or canceled outright. The total number of funded investigators dropped by nearly 2,000 in FY2025.

For biotech, this is like a football team cutting its scouting budget. You might save money today, but you're going to miss the next generation of talent.

The Spending Crossover Is Coming

The broader R&D picture is even more striking. According to NCSES data, total U.S. R&D spending (public and private combined) was approximately $940 billion in 2023. China's figure? Climbing every year while U.S. federal investment has stayed flat, adjusted for inflation, over two decades.

Some analysts believe China has already surpassed the U.S. in total R&D spending, depending on how you measure it. In 2024 purchasing power parity terms, the numbers were nearly identical: China at roughly $786 billion, the U.S. at about $782 billion. China's government-run research labs already spend more than 1.5 times what their American counterparts do.

And there's a hidden multiplier. Because labor costs are lower in China, every research dollar goes further. One estimate suggests $100,000 supports 2.3 researchers in China versus just one in the United States. That's not just a cost advantage; it's a productivity advantage.

What This Means for Investors and the Industry

The gene therapy market is projected to reach approximately $10 billion in 2026. By the mid-2030s, forecasts range as high as $78 billion. The Asia-Pacific region is expected to grow fastest, at nearly 29% annually through 2031.

Smart money is already flowing accordingly. AstraZeneca acquired Chinese CAR-T specialist Gracell Biopharma in 2023 to get access to next-generation cell therapy platforms. Legend Biotech, which co-developed the blockbuster Carvykti (one of seven FDA-approved CAR-T products), continues to build out its pipeline from its China operations.

The strategic calculus for investors is shifting. North America still holds the largest share of the global gene therapy market thanks to its deep infrastructure and private investment. But China's trial volume, cost advantages, and manufacturing scale make it the growth story. The companies that figure out how to bridge both ecosystems will likely win.

The Real Risk Isn't Losing a Race

This isn't really about national pride or who plants a flag first. It's about patients. More trials mean more data. More data means better treatments, developed faster. If the U.S. slows down while China speeds up, the practical result is that American patients could end up waiting longer for therapies that Chinese patients already have access to.

The U.S. still has enormous strengths: world-class universities, a deep bench of scientific talent, the FDA's gold-standard regulatory framework, and a private sector that pours billions into biotech R&D. None of that disappears overnight.

But advantages don't last forever on autopilot. CAR-T therapy was an American invention. Whether the next generation of cell therapies will be is increasingly an open question.

The Insulin Pump That Ditched Its Screen

MiniMed just got FDA clearance for the Flex, an insulin pump that's half the size of its predecessor and has no screen at all. In a market dominated by Insulet's tubeless Omnipod, this is MiniMed's boldest move yet to prove it can compete on lifestyle appeal.